TriSalus Life Sciences, Inc. (NASDAQ:TLSI) is among the 11 Fastest Growing Penny Stocks to Buy Right Now. Canaccord Lowers its Price Target on TriSalus Life Sciences, Inc. (TLSI) to $7 from $12 and Maintains a Buy Rating On March 6, 2026, Canaccord analyst William Plovanic lowered the price target on TriSalus Life Sciences, Inc. (NASDAQ:TLSI) to $7 from $12 previously and maintained a Buy rating. William Plovanic said Q4 results came in line with the company’s preannouncement and that guidance was reiter ...

Financial Data and Key Metrics Changes - Fourth quarter revenues were $13.2 million, representing a 60% increase year-over-year, while full-year revenues were $45.2 million, reflecting a 53% increase compared to the previous year [6][26] - Gross margin for the fourth quarter improved to 87% from 85% in the prior year, driven by better manufacturing efficiency [24] - Net operating loss for the quarter was $3.3 million, a significant decrease from $7.6 million in the prior year [25] - Adjusted EBITDA loss for the quarter was approximately $950,000, an improvement from a loss of $5.7 million in the prior year [25] Business Line Data and Key Metrics Changes - Revenue from the TriNav system for the full year was $45 million, a 53% increase compared to the previous year, primarily driven by increased sales in liver-directed therapies [26] - Research and development expenses decreased by $2.7 million for the year, mainly due to the closeout of clinical trial expenses related to nelitolimod [27] - Sales and marketing expenses increased by $2.9 million for the year, attributed to higher performance-related compensation due to increased sales [28] Market Data and Key Metrics Changes - The total addressable market for liver embolization procedures is approximately $480 million, while the broader embolization market, including thyroid and uterine artery embolization, represents a $2.3 billion opportunity [15][16] - The introduction of the CMS HCPCS code C8004 expanded coverage for simulation or mapping procedures using TriNav, effectively doubling the reimbursable use of the technology [16] Company Strategy and Development Direction - The primary strategic priority is to expand sales and commercial infrastructure, with plans to nearly double the commercial footprint [9][10] - The company is investing in foundational clinical studies to validate the Pressure-Enabled Drug Delivery (PEDD) platform, which is expected to drive growth in 2027 and beyond [9] - The product portfolio is expanding from two core products at the beginning of 2025 to seven differentiated offerings by 2026, enhancing sales productivity [12] Management's Comments on Operating Environment and Future Outlook - Management reaffirmed revenue guidance for 2026 in the range of $60 million to $62 million, with growth expected to be weighted towards the second half of the year [9][22] - The company anticipates that the significant investment in the sales force will lead to stronger productivity and revenue growth exiting 2026 [10] - Management emphasized the importance of clinical data releases in driving adoption of new applications, particularly in non-liver areas [33][60] Other Important Information - The company raised $46 million in gross proceeds through a public offering, which was oversubscribed and supported by experienced healthcare investors [8][30] - The company is awaiting FDA clearance for the TriNav Advance product, which is expected to enhance therapeutic delivery and expand market opportunities [15][49] Q&A Session Summary Question: Contribution to growth in 2026 from liver versus non-liver - Management indicated that liver will still be the majority of revenue in 2026, but expects meaningful progress in new applications tied to data releases in the second half of the year [33] Question: Balancing growth cadence and EBITDA pathway - Management is not providing specific timing on cash flow or adjusted EBITDA breakeven but is focused on investments to scale the company meaningfully [34][35] Question: Details on the sales organization structure after investments - Management confirmed that the commercial organization will be significantly expanded, including adding a layer of management to improve sales effectiveness [39][40] Question: Growth expectations for mapping and simulation - Management expressed confidence in growth from TriNav XP and TriNav Advance, which are expected to enhance mapping capabilities [46][48] Question: Use patterns for the TriNav product portfolio - Management noted varied use patterns among physicians, with some preferring specific products while others seek access to the full portfolio for clinical flexibility [52][56] Question: Long-term opportunities for TriNav in liver versus non-liver - Management highlighted that liver will remain a significant component of sales, but sees substantial growth potential in thyroid artery embolization and other new applications [60][62]

Financial Data and Key Metrics Changes - Fourth quarter revenues were $13.2 million, representing a 60% increase year-over-year, while full-year revenues were $45.2 million, reflecting a 53% increase compared to the previous year [6][26] - Gross margin for the fourth quarter improved to 87% from 85% in the prior year, driven by better manufacturing efficiency [24] - Net operating loss for the fourth quarter was $3.3 million, a significant decrease from $7.6 million in the prior year [25] - Adjusted EBITDA loss for the quarter was approximately $950,000, an improvement from a loss of $5.7 million in the prior year [25] Business Line Data and Key Metrics Changes - Revenue from the TriNav system for the full year was $45 million, a 53% increase compared to the previous year, primarily driven by increased sales in liver-directed therapies [26] - Research and development expenses decreased by $2.7 million for the year, largely due to the closeout of clinical trial expenses related to nelitolimod [27] - Sales and marketing expenses increased by $2.9 million for the year, attributed to higher performance-related compensation due to increased sales [28] Market Data and Key Metrics Changes - The total addressable market for liver embolization procedures is approximately $480 million, while the broader embolization market represents a $2.3 billion U.S. addressable market [15][16] - The introduction of a new CMS HCPCS code expanded coverage for simulation or mapping procedures, effectively doubling the reimbursable use of the technology [16] Company Strategy and Development Direction - The primary strategic priority is to expand sales and commercial infrastructure, with plans to double the commercial footprint and enhance clinical studies to validate the PEDD platform [9][10] - The company aims to launch TriNav Advance in the first half of 2026, which is expected to facilitate selective therapy delivery and enhance therapeutic delivery to tumors [15] - The company is focused on executing near-term milestones, including achieving annual revenue in the range of $60 million-$62 million for 2026 [22] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the long-term value of the PEDD platform and the growth opportunities ahead, despite the need for upfront investments affecting near-term revenue [10][11] - The company anticipates that the revenue cadence will build throughout 2026 as the commercial expansion and new product contributions progress [10] - Management highlighted strong physician engagement and interest in the PEDD platform, indicating a positive outlook for future adoption [10] Other Important Information - The company raised $46 million in gross proceeds through a public offering, which was oversubscribed and supported by experienced healthcare investors [8] - The company is preparing to release a consolidated clinical update for the nelitolimod program in the second half of 2026, focusing on presenting a complete dataset for potential partners [21] Q&A Session Summary Question: Contribution to growth in 2026 from liver versus non-liver - Management indicated that liver will still be the majority of revenue in 2026, with expectations for meaningful progress in new applications in the second half of the year [33] Question: Balancing growth cadence and EBITDA pathway - Management stated that specific timing or guidance on cash flow breakeven or adjusted EBITDA breakeven is not being provided at this time, as they are in the early stages of investing in commercial expansion [34] Question: Details on the sales organization structure after investments - Management confirmed that they are significantly doubling the size of the commercial organization and adding a layer of management to improve sales opportunities [38] Question: Growth expectations for mapping and simulation - Management expressed confidence in growth from mapping and simulation, particularly with the introduction of new products like TriNav XP and TriNav Advance [44] Question: Use patterns for the TriNav product portfolio - Management noted varied use patterns among physicians, with some preferring specific products while others seek access to the full portfolio for clinical flexibility [50]

Financial Data and Key Metrics Changes - Fourth quarter revenues were $13.2 million, representing a 60% increase year-over-year, while full-year revenues were $45.2 million, a 53% increase compared to the previous year [5][21] - Gross margin for the fourth quarter improved to 87% from 85% in the prior year, driven by better manufacturing efficiency [21] - Net operating loss for the quarter was $3.3 million, down from $7.6 million in the prior year, reflecting increased revenue and margin contribution [22] - Adjusted EBITDA loss for the quarter was approximately $950,000, an improvement from a loss of $5.7 million in the prior year [22] Business Line Data and Key Metrics Changes - Revenue from the TriNav system for the year was $45 million, a 53% increase compared to the previous year, primarily driven by increased sales in liver-directed therapies [23] - Research and development expenses decreased by $2.7 million for the year, mainly due to the closeout of clinical trial expenses related to nelitolimod [24] - Sales and marketing expenses increased by $2.9 million for the year, attributed to higher performance-related compensation due to increased sales [24] Market Data and Key Metrics Changes - The total addressable market for liver embolization procedures is approximately $480 million, while the broader embolization market represents a $2.3 billion opportunity [13][14] - The introduction of a new CMS HCPCS code expanded coverage for simulation or mapping procedures using TriNav, effectively doubling the reimbursable use of the technology [14][15] Company Strategy and Development Direction - The primary strategic priority is to expand sales and commercial infrastructure, with plans to double the commercial footprint and enhance clinical studies to validate the PEDD platform [7][9] - The company aims to launch TriNav Advance in the first half of 2026, which is expected to facilitate selective therapy delivery to small distal vessels [13] - The strategy includes conducting foundational studies to prove the superiority of the technology in liver embolization, which is expected to drive long-term penetration in the market [55] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving revenue guidance of $60 million to $62 million for 2026, with growth weighted towards the second half of the year [9][19] - The company noted strong physician engagement and interest in the PEDD platform, indicating a positive outlook for future demand [10] - Management emphasized the importance of investing in commercial infrastructure and clinical evidence to support long-term growth [7][20] Other Important Information - The company raised $46 million in gross proceeds through a public offering, which was oversubscribed and supported by experienced healthcare investors [6][26] - The company is focused on executing near-term milestones, including launching TriNav Advance and publishing clinical data across various indications [19][20] Q&A Session Summary Question: Contribution from liver versus non-liver growth in 2026 - Management indicated that liver will still be the majority of revenue in 2026, with expectations for meaningful progress in non-liver applications tied to data releases later in the year [28][29] Question: Balancing growth cadence and EBITDA pathway - Management stated that specific timing or guidance on cash flow breakeven or adjusted EBITDA breakeven is not being provided at this time, as investments in commercial expansion are ongoing [30] Question: Details on the sales organization structure after investments - Management confirmed that the commercial organization will be significantly expanded, including adding a layer of management to improve sales opportunities [34][35] Question: Growth expectations for mapping and simulation - Management expressed confidence in growth from mapping and simulation, particularly with the introduction of new products like TriNav XP and TriNav Advance [40][41] Question: Use patterns for the TriNav product portfolio - Management noted varied use patterns among physicians, with some preferring specific products while others seek access to the full portfolio for clinical flexibility [48][52] Question: Long-term opportunities for TriNav in liver versus non-liver - Management highlighted that liver will remain a significant component of sales, but there are substantial growth opportunities in non-liver applications, particularly in thyroid artery embolization [54][56]

Financial Performance - TriNav achieved $45.2 million in revenue in 2025, representing growth of 53.4% compared to the previous year[24]. - The company incurred net losses of $39.2 million and $30.0 million for the years ended December 31, 2025 and 2024, respectively, with an accumulated deficit of $330.6 million as of December 31, 2025[168]. - The company is highly dependent on the sales of its TriNav device for revenue generation, and any decline in market acceptance could adversely affect its business[166]. - The estimated market opportunity for TriNav's current portfolio is approximately 62,000 units, translating to about $494 million based on a unit price of $7,983[46]. - The total addressable market for TriSalus PEDD technology in the U.S. is projected to exceed $2.3 billion annually, with a current market valued at $1 billion and an additional opportunity of $1.3 billion[54]. Product Development and Clinical Trials - The PRVI device for pancreatic tumors is currently in a Phase I trial and is not expected to be commercialized before 2026[28]. - TriSalus is supporting two Investigator Initiated Trials of nelitolimod, with results expected in 2026[31]. - The company has completed Phase 1 and Phase 1b clinical trials for nelitolimod, focusing on various cancers[198]. - The company has initiated three Phase 1/1b Pressure Enabled Regional Immuno-oncology (PERIO) studies targeting uveal melanoma with liver metastases, intrahepatic cholangiocarcinoma (ICC), and locally advanced pancreatic carcinoma, with results expected in 2026[80][82]. - The company is seeking partners for funding to advance nelitolimod development in Phase II trials, with results expected in 2026[198]. Technology and Innovation - The PEDD technology has been used in over 31,000 procedures, primarily for TACE and TARE[24]. - In clinical studies, PEDD devices demonstrated a 33% to 90% increase in tumor deposition and a 24% to 89% decrease in nontarget embolization compared to standard catheters[39]. - The SmartValve technology in PEDD devices preserves over 70% of forward blood flow, enhancing therapeutic delivery[34]. - TriSalus's PEDD technology is designed to overcome high intratumoral pressure, improving drug delivery to solid tumors[33]. - TriNav's technology aims to overcome mechanical barriers in tumor microenvironments, enhancing therapeutic delivery while minimizing toxicity[68]. Regulatory and Compliance - The company is subject to extensive regulation by the FDA and other agencies, impacting the cost and time needed for product approvals[106]. - The FDA's 510(k) review process typically takes three to six months, but may extend longer depending on the information required[110]. - The PMA process for Class III devices requires extensive data, including preclinical studies and human clinical trials, and can take up to several years for FDA review[113]. - The FDA may approve a PMA application with post-approval conditions to ensure ongoing safety and effectiveness of the device[114]. - The company must conduct clinical trials under protocols reviewed by the FDA and approved by Institutional Review Boards (IRBs)[123]. Market and Competitive Landscape - Approximately 137,000 new cases of primary and secondary liver cancers and over 60,000 cases of pancreatic cancer are diagnosed annually in the U.S., with more than 80,000 cases potentially addressable through the nelitolimod/PEDD platform[86][87]. - The five-year survival rate for pancreatic ductal adenocarcinoma (PDAC) is only 13%, highlighting a significant unmet medical need and market opportunity for nelitolimod[87]. - Intense competition in the biopharmaceutical and medical device industries may hinder market establishment and growth[218]. - Factors influencing market acceptance include disease severity, trial design, and competition from alternative therapies[208]. Financial and Operational Risks - The company may require substantial additional capital to finance operations and product development, and there is uncertainty regarding the availability of such financing[169]. - The company has identified material weaknesses in its internal control over financial reporting, which could affect its ability to report financial results accurately[170]. - The company faces risks related to potential acquisitions or strategic transactions that may disrupt ongoing operations and negatively impact results[179]. - The company may need to seek partners for its product candidates at an earlier stage or on less favorable terms, which could harm its business prospects[174]. - The company is currently in compliance with the covenants of the OrbiMed Credit Agreement, but failure to meet certain milestones could lead to an event of default[177]. Reimbursement and Pricing - TriSalus received a unique and permanent HCPCS code (C9797) from CMS with a payment rate of $17,957 for embolization procedures, enhancing reimbursement clarity[55]. - A New Technology HCPCS code (C9797) for procedures involving TriNav was granted by CMS, effective January 1, 2024[154]. - The reimbursement process is complex and may involve delays, affecting actual revenue received[216]. - Changes in third-party coverage and reimbursement could materially impact the ability to sell products profitably[213]. - Any reduction in TriNav's reimbursement could materially decline sales and hinder market adoption[195].

Financial Results - TriSalus Life Sciences, Inc. announced preliminary unaudited financial results for Q4 2025 and provided revenue guidance for 2026[6]. - The press release detailing the financial results was issued on January 12, 2026[6]. - The financial statements and exhibits related to the report are included in Exhibit 99.1[8]. Company Information - The company is listed on the Nasdaq Global Market under the trading symbol TLSI[4]. - The company has not indicated whether it is an emerging growth company[5]. - The report was signed by David Patience, Chief Financial Officer, on January 12, 2026[12].

Core Insights - TriSalus Life Sciences, Inc. (TLSI) has received a Zacks Rank 2 (Buy) upgrade due to an upward trend in earnings estimates, which is a significant factor influencing stock prices [1][3] - The Zacks rating system is based on changes in earnings estimates, making it a valuable tool for investors to gauge stock performance [2][4] Earnings Estimates and Stock Performance - The correlation between changes in earnings estimates and stock price movements is strong, with institutional investors using these estimates to determine fair value [4][5] - For TriSalus Life Sciences, the increase in earnings estimates indicates an improvement in the company's business fundamentals, likely leading to higher stock prices [5][10] Zacks Rank System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with a proven track record of Zacks Rank 1 stocks generating an average annual return of +25% since 1988 [7] - The upgrade to Zacks Rank 2 places TriSalus Life Sciences in the top 20% of Zacks-covered stocks, suggesting potential for market-beating returns in the near term [10] Earnings Estimate Revisions - For the fiscal year ending December 2025, TriSalus Life Sciences is expected to earn -$1.79 per share, unchanged from the previous year, but the Zacks Consensus Estimate has increased by 6.7% over the past three months [8]

Company Overview - TriSalus Life Sciences is focused on improving outcomes for patients with solid tumors, specifically in the liver and pancreas [2] - The company utilizes a platform technology that modulates pressure and flow to enhance therapy delivery directly into tumors while minimizing off-target effects [2] Innovative Approach - Dr. Juan Camacho has developed a new approach for Thyroid Artery Embolization, which is part of TriSalus's innovative strategies [2]

Summary of Trisalus Life Sciences Conference Call Company Overview - **Company**: Trisalus Life Sciences (NasdaqGM: TLSI) - **Focus**: Improving outcomes for patients with solid tumors in the liver, pancreas, and other areas through innovative delivery technologies [2][3] Core Technology and Market Opportunity - **Technology**: A catheter-based system that modulates pressure and flow to enhance drug delivery directly into tumors, minimizing off-target effects [3][4] - **Market Size**: The company operates in a market opportunity of approximately $500 million, with less than 10% market share currently [3][4] - **Growth Potential**: Rapid growth anticipated due to the versatility of the technology for various embolization applications [4] Innovations in Treatment - **Thyroid Artery Embolization**: A new approach developed by Dr. Juan Camacho, aimed at treating multinodular goiter as a minimally invasive alternative to surgery [10][12] - **Patient Outcomes**: The technology has shown a 50% reduction in post-procedure readmissions due to fewer complications [8][9] Multinodular Goiter Insights - **Prevalence**: Approximately 12% of the adult population worldwide has multinodular goiter, with a significant number undergoing thyroidectomies annually [17][18] - **Surgical Risks**: Many surgeries are performed by general surgeons, leading to disparities in outcomes compared to specialized surgeons [18][19] - **Symptoms and Complications**: Patients often experience significant morbidity, including hyperthyroidism and compressive symptoms [21][23] Treatment Paradigms - **Minimally Invasive Options**: Options include radioactive iodine, percutaneous ethanol injection, ablation, and thyroid artery embolization [25][31] - **Volume Considerations**: Larger nodules (>20 mL) are more effectively treated with thyroid artery embolization due to high recurrence rates with other methods [27][28] Clinical Evidence and Results - **Efficacy of Embolization**: Studies indicate that thyroid artery embolization can reduce thyroid volume by approximately 50% and improve hormone levels without causing hypothyroidism [36][37] - **Quality of Life Improvements**: Significant improvements in quality of life reported post-procedure, with a high euthyroid conversion rate in patients with hyperthyroidism [38][39] Future Directions - **Research and Guidelines**: Ongoing efforts to build robust clinical data and establish guidelines for patient selection and treatment protocols [54][56] - **Awareness and Training**: Emphasis on increasing awareness of the procedure among patients and healthcare providers, and ensuring proper training for practitioners [64][65] Conclusion - **Emerging Treatment**: Pressure-enabled thyroid artery embolization presents a promising alternative for patients with large goiters, particularly when surgery poses high risks [52][53] - **Multidisciplinary Approach**: Collaboration among various specialties is crucial for optimizing patient care and integrating this technology into standard practice [64][65]

Summary of Trisalus Life Sciences FY Conference Call Company Overview - **Company**: Trisalus Life Sciences (NasdaqGM: TLSI) - **Industry**: Oncology-focused medical technology - **Market Opportunity**: $2.5 billion market in liver embolization procedures, currently growing at over 50% per year [2][24] Core Technology and Innovations - **Technology**: Catheter-based system that enhances drug delivery to tumors while minimizing exposure to normal tissue - **Patent Portfolio**: Over 100 patents, with 20-25 patents filed annually, focusing on pressure modulation for optimal tumor perfusion [3][2] - **Drug Delivery Efficiency**: Achieves 50%-500% more drug delivery to tumors compared to traditional methods [7][8] Clinical and Economic Impact - **Patient Outcomes**: Improved overall survival rates and reduced complications due to targeted drug delivery [8][10] - **Cost Savings**: CMS saves approximately $8,000 per procedure due to reduced hospital readmissions [10][11] - **Reimbursement**: Favorable reimbursement landscape with a proprietary embolization code, enhancing hospital revenue [13][10] Product Portfolio and Market Penetration - **Current Devices**: Two devices launched in 2020 and 2021, with plans to introduce two additional sizes to cater to various vascular anatomies [11][12] - **Market Share**: Currently holds a 9% share in the liver embolization market, with significant growth potential [14] - **Expansion into Other Applications**: Technology is being adapted for uterine fibroids, thyroid nodules, and pancreatic treatments, among others [15][19][20] Future Growth Opportunities - **New Applications**: Exploring embolization procedures for osteoarthritis and other orthopedic conditions, which could significantly change treatment paradigms [22][23] - **Collaborations**: Partnerships with other drug companies to enhance drug delivery systems and improve treatment outcomes [20][21] - **Market Strategy**: Targeting 400 hospitals and 1,000 doctors, focusing on a concentrated market approach [13][14] Financial Outlook - **Growth Guidance**: Current year growth projected at 50%, with future guidance under review [28] - **Cost Management**: Focus on reducing R&D and G&A expenses while maintaining positive Adjusted EBITDA by mid-year [29][30] - **Revenue Performance**: Achieved approximately $12 million in revenue last quarter, with gross margins around 85% [30][31] Additional Insights - **Unique Selling Proposition**: The technology's ability to modulate pressure and flow allows for better treatment outcomes and minimizes complications [6][7] - **Regulatory Strategy**: Plans to gather clinical data to support inclusion in treatment guidelines, which could drive adoption [26][27] This summary encapsulates the key points discussed during the Trisalus Life Sciences FY Conference Call, highlighting the company's innovative technology, market opportunities, and financial outlook.